AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
1min snip
Novo Nordisk (Ozempic)
Acquired
Researching Oral Anti-Diabetic Drugs
Novo Nordisk, a leader in insulin production, has never had a viable oral anti-diabetic drug. Lata, a member of a group seeking new candidates, discovers that increasing the hormone GLP one in type two diabetes patients could stabilize insulin production. Initially thinking it would be easy to genetically engineer more GLP one, Lata realizes it's not that simple and suggests consuming GLP one directly. Will this unconventional approach work?
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode